Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk Markers

Johnson, Jeremiah X.; Lowell, Jane; Badger, Gary J.; Rosing, Jan; Tchaikovski, Svetlana; Cushman, Mary

doi:10.1097/aog.0b013e3181626d1b

Cited by 64 publications

(46 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are published data regarding the use of COCs and their impact on vWF level that confirm our finding. 25,37 The FVII activity levels were higher among both CHC user groups, as compared to the control group. The CVC users in our study had a lower level of FVII than the COC users (though not statistically significantly lower).…”

Section: Discussionmentioning

confidence: 95%

Oral Versus Vaginal Combined Hormonal Contraceptives' Effect on Coagulation and Inflammatory Biomarkers Among Young Adult Women

Divani

Luo

Brandy

et al. 2012

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

In order to compare the effect of combined oral contraceptive (COC) and combined vaginal contraceptive (CVC) methods on the inflammation and procoagulation, we recruited female participants in 3 groups: control participants, COC users, and CVC users. We measured different blood biomarkers. The users of both COC and CVC had higher levels of C-reactive protein (P < .0001) and factor VII (P < .0001). However, CD40 ligand was only higher for COC users (P < .0001) and not the CVC users. Even though the levels of thrombin/antithrombin III were not higher for COC and CVC users, as compared to the controls, CVC users had higher levels as compared to COC users (P ¼ .0327). As compared to the control group, we observed higher levels von Willebrand factor among CVC users but not the COC users. Longitudinal studies with larger sample size are needed to better assess the inflammatory and procoagulation response due to CVC use.

show abstract

Section: Discussionmentioning

confidence: 95%

Oral Versus Vaginal Combined Hormonal Contraceptives' Effect on Coagulation and Inflammatory Biomarkers Among Young Adult Women

Divani

Luo

Brandy

et al. 2012

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…The dosing and formulation of the patch medication is also important, as recently demonstrated for a contraceptive patch. 10 At this time, surrogate end point data, when taken together with the observational data available, is not sufficient to support safety from the venous thrombosis perspective. A large clinical trial or further observational studies supporting this hypothesis are needed.…”

Section: See Accompanying Article On Page 340mentioning

confidence: 99%

Patch Instead of Pill

Cushman

2010

ATVB

Self Cite

View full text Add to dashboard Cite

“…However, in a recent randomized, investigator-blinded, crossover clinical trial of 24 women 18 to 35 years of age, transdermal and oral contraceptives had similar statistically significant adverse effects on vascular risk markers. 709 Recent assessment of the etonogestrel-releasing implant suggested that these implants did not induce a prothrombotic state during the first 6 months of use. 710 Confounding factors such as vascular health, timing of medication administration, route of delivery, smoking, diabetes mellitus, insulin resistance, obesity, and genetically increased risk for thromboembolism affect the risk of thrombosis in individual patients.…”

Section: Oral Contraceptivesmentioning

confidence: 99%